Kaitlyn Bader, Assistant Managing Editor

After TMB-001 did not meet its primary end point in the ASCEND trial, LEO Pharma moved to out-license the vehicle formulation, which unexpectedly provided a response in 40% of patients.

In a recent Expert Perspectives video series, Omar Noor, MD, discussed the complexity of chronic hand eczema and how a topical pan-JAK inhibitor can improve quality of life.

In the latest Cutaneous Connection podcast episode, Renata Block, DMSc, MMS, PA-C, and patient advocate Suki Tipp discuss the clinical, emotional, and financial toll of delayed diagnosis of indolent systemic mastocytosis.

Patient advocate Suki Tipp details her progression from misattributed cutaneous findings and fragmented specialty care to life-threatening anaphylaxis and eventual disease control with targeted therapy.

Castle Biosciences’ AdvanceAD-Tx test stratifies patients by molecular profile, identifying patients more likely to achieve faster and deeper responses with JAKs compared with Th2-targeted treatments.

Around 800 rare skin diseases affect 6.8 million people worldwide, including epidermolysis bullosa, generalized pustular psoriasis, ichthyosis, and erythropoietic protoporphyria.

Todd Schlesinger, MD, highlights data supporting red light–activated PDT with 10% ALA gel for superficial basal cell carcinoma, discussing structured treatment protocols and manageable tolerability.

Todd Schlesinger, MD, reviews emerging randomized trial data supporting red light–activated photodynamic therapy with 10% aminolevulinic acid gel and outlines key considerations for patient selection in superficial basal cell carcinoma (sBCC).

Todd Schlesinger, MD, discusses emerging evidence, clearance outcomes, and practical considerations for using red light–based photodynamic therapy as a nonsurgical option in select superficial basal cell carcinoma (BCC) cases.

Aminex Therapeutics has initiated a trial evaluating AMXT 1501 and DFMO, with implications for dermatologists managing advanced melanoma.

Firas G. Hougeir, MD, and clinician attendees discussed how to use real-world patient scenarios to determine optimal timing for biologic initiation for patients with moderate to severe HS.

DELTA CARE 1 is the first phase 3 investigation of a pan–Janus kinase inhibitor specifically for lichen sclerosus.

Discover insights from the Horizons in Advanced Practice meeting on type 2 inflammation and psoriasis management.

Phase 1 cohort 4 data show soquelitinib demonstrated sustained clinical activity through 8 weeks, including in patients with prior systemic therapy exposure.

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis

Psoriasis impacts physical and emotional health, with hidden burdens like trauma and IPV affecting quality of life and care access.

At the Dermatology Times Horizons in Advanced Practice meeting in Tampa, Florida, conference chair Lakshi Aldredge, MSN, ANP-BC, DCNP, focused a discussion on efficacy data for adalimumab, secukinumab, and bimekizumab.

Mabwell’s investigational 9MW3811 is the first IL-11–targeting therapy to enter clinical evaluation for pathological scarring.

Discover key insights from the 2025 Fall Clinical Dermatology Conference, featuring advancements in eczema, skin cancer testing, and pediatric psoriasis therapies.

John Barbieri, MD, MBA; Ted Rosen, MD; Peter Lio, MD; Shanna Miranti, MPAS, PA-C; and Larissa Schmidt, DPM, share what gifts they would give to the field of dermatology this holiday season.

As 2025 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.

Hilary Baldwin, MD; Douglas DiRuggiero, DMSc, MHS, PA-C; Diego Ruiz DaSilva, MD; Ken Korber, PA-C; Patrick Burnett, MD, PhD; and Lisa Weiss, PA-C, share what gifts they would give to the field of dermatology this holiday season.

Experts discuss innovative strategies for vitiligo treatment, emphasizing the role of topical Janus kinase inhibitors and effective patient communication for optimal outcomes.

At a recent Case-Based Roundtable event, Harrison Nguyen, MD, MBA, MPH, reviewed 2 HS patient cases and discussed the role of biologics.

Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed the 3 latest non-steroidal topicals for atopic dermatitis at the Horizons in Advanced Practice meeting.

Omar Noor, MD, recently presented 3 cases of psoriasis in older patients at Horizons in Advanced Practice to discuss available treatment options and considerations for Medicare and in-office injections.

At a recent Case-Based Roundtable® event, Aaron Farberg, MD, moderated a discussion of challenging atopic dermatitis cases spanning adult, adolescent, and pediatric patients.

Early-phase development introduces a potential first-in-class oral approach targeting type 2 inflammation relevant to dermatologic diseases.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed psoriasis in high-impact sites, overall psoriatic disease, and available therapies.

Topline results are expected in the first quarter of 2026.